drugset / Trial / NCT01129648
Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
RandomizedFactorialQuadruple-blindTreatment
Summary
To evaluate safety and efficacy of BCX4208 alone and in combination with allopurinol in subjects with gout.
Timeline
- Start
- 2010-05
- Primary completion
- 2010-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allopurinol | Small molecule | 100 mg | — |
| Subject | Allopurinol | Small molecule | 200 mg | — |
| Subject | Allopurinol | Small molecule | 300 mg | — |
| Subject | Ulodesine | Small molecule | 20 mg | — |
| Subject | Ulodesine | Small molecule | 40 mg | — |
| Subject | Ulodesine | Small molecule | 80 mg | — |